Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $160.9352W HIGH $242.80
Volume
3.92 M
Value Traded
761.15 M
Short % Float
1.31%
+3.88%Week
-11.32%1 Month
-17.6%3 Month
-22.78%6 Month
-24.07%5 Year
+28,772.96%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
150.48 B
EPS (TTM)
5.20
P/E Ratio
33.24
Ent. Value
135.73 B
Total Shares
703.06 M
Float Shares
638.87 M
Insiders
9.12%
Institutions
84.54%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DHR Catalyst Timeline
Dated clinical, regulatory and corporate events for Danaher Corporation
Past FDA Catalysts and PDUFA Decisions
How DHR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Danaher Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every DHR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Blair RainerDirector, Officer (President & CEO) | Sell | -11,307 46,948 held | $217.77 | 08/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DHR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.4 % | 43.81 M | 230.00 K | 93.96% ( 111.42 K) |
DHR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DHR ranks across every disease it competes in
Competitive Position is a premium feature
See how DHR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDHR News
DHR▲ +1.1%today
Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer
Julie Sawyer Montgomery has officially taken on the roles of President and CEO of Danaher Corporation, effective October 1, 2026. She has been with the company since 2017, holding various leadership positions that have contributed to its growth and innovation. Rainer Blair will assist in the transition as a senior advisor until March 31, 2027.
Read more →DHRDanaher Schedules Third Quarter 2026 Earnings Conference Call
Danaher Corporation has scheduled its third quarter 2026 earnings conference call for October 21, 2026. The call will cover financial performance and future expectations, lasting approximately one hour. Investors can access the call via a dedicated phone line or through a webcast on Danaher's website, with a replay available afterward.
Read more →DHRDanaher Announces Quarterly Dividend
Danaher Corporation has declared a quarterly cash dividend of $0.40 per share, set to be paid on October 30, 2026, to shareholders on record as of September 30, 2026. This announcement highlights Danaher's ongoing commitment to returning value to its shareholders while maintaining a focus on innovation in life sciences and diagnostics.
Read more →DHRDanaher to Present at Bank of America Securities Healthcare Conference
Danaher Corporation's CEO, Rainer M. Blair, will present at the Bank of America Securities Healthcare Conference on May 13, 2026. The event will take place in Las Vegas and will be available via webcast. Danaher is recognized for its innovative contributions to life sciences and diagnostics, aiming to enhance human health.
Read more →DHR▼ -5.4%on this news
Danaher Announces Pricing of Euro-Denominated Senior Notes Offering
Danaher Corporation has announced the pricing of a euro-denominated senior notes offering totaling €2.98 billion. The offering includes various notes with different maturities and interest rates, aimed at funding the acquisition of Masimo Corporation. The closing of the offering is anticipated on April 29, 2026, pending customary conditions.
Read more →DHRDanaher Reports First Quarter 2026 Results
Danaher Corporation reported strong first quarter results for 2026, with net earnings reaching $1.0 billion and a 9.5% increase in adjusted diluted earnings per share. Revenues rose 3.5% year-over-year, driven by growth in Bioprocessing and Life Sciences. The company also announced plans to acquire Masimo Corporation, which is expected to enhance its capabilities in patient monitoring. However, a lighter-than-expected respiratory season at Cepheid posed challenges.
Read more →DHRBeckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes
Beckman Coulter Diagnostics has received CE mark approval for its Access MeMed BV assay, which allows for rapid differentiation between bacterial and viral infections in about 20 minutes. This assay can significantly reduce healthcare costs in Europe by minimizing unnecessary admissions and testing. By leveraging existing laboratory infrastructure, it aims to enhance clinical decision-making and support antimicrobial stewardship.
Read more →DHRDanaher Schedules First Quarter 2026 Earnings Conference Call
Danaher Corporation has scheduled its first quarter 2026 earnings conference call for April 21, 2026, at 8:00 a.m. ET. The call will cover the company's financial performance and future expectations. A replay will be available after the call, along with related materials on Danaher's website.
Read more →DHRDanaher To Acquire Masimo Corporation
Danaher Corporation has announced its agreement to acquire Masimo Corporation for $180 per share, totaling approximately $9.9 billion. This acquisition aims to enhance Danaher's diagnostics capabilities, particularly in acute care settings. The deal is expected to close in the second half of 2026, pending regulatory and shareholder approvals. Danaher anticipates significant synergies and revenue growth from the acquisition.
Read more →DHRDigital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
In a recent episode of Denatured, experts from Danaher Corporation discuss the impact of digital pathology and artificial intelligence on HER2 cancer treatment. Dr. Rob Monroe and Jennifer Fakish highlight how these technologies facilitate accurate measurement of HER2 levels, ensuring patients receive the most effective antibody-drug conjugate (ADC) treatments. The conversation underscores the advancements in oncology driven by innovative technologies.
Read more →About Danaher Corporation
Headquarters2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC, 20037-1701
BIOPHARMAWATCH ELITE PLUS
Trade the next DHR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime